Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Kidney and Cardiovascular Endpoints in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China

NCT07900438 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07900438 Recruiting Phase 4 300 participants (estimated) Started 2026 26 sites

Follow this trial by email Email me the PDF

Get the NCT07900438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Recruiting, started October 2026. Interventional study, Phase 4, 300 participants (estimated). Lead sponsor Novo Nordisk A/S; China. Primary measure: Time to first occurrence of a composite endpoint consisting of: Onset of persistent reduction of ≥ 50%...

How it compares

312 similar trials: same condition (Renal Insufficiency, Chronic) and phase

Enrollment

This trial
300
Middle half
30 to 202
Median
70
Trials with a value
310

Months from start to completion

This trial
39.4
Middle half
16 to 45
Median
27
Trials with a value
301

Sites

This trial
26
Middle half
1 to 2
Median
1
Trials with a value
276
Posted results or a linked paper 54% 167 of 312 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Kidney and Cardiovascular Endpoints in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Recruiting
Start date
October 12, 2026
Completion date
January 24, 2030
Enrollment
300 (estimated)
Sites
26

Conditions

MeSH condition names; the registry's own terms follow.

Renal Insufficiency, Chronic

Registry terms: cardiovascular risk, chronic kidney disease

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
26
Countries
China
Lead sponsor
Novo Nordisk A/S

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
Semaglutide Experimental Semaglutide
Show registry wording

Participants will receive subcutaneous injection of semaglutide once weekly.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Time to first occurrence of a composite endpoint consisting of: Onset of persistent reduction of ≥ 50% in eGFR compared with baseline, Onset of persistent eGFR < 15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death, CV death From Baseline (Week 0) up to Week 169
Show registry wording

Measured in month(s)

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Semaglutide 41 Orange Book patentsPatent cliff February 17, 2041 (Orange Book patent)
    • US 11318191; expires February 17, 2041; assignee Novo Nordisk A S
    • US 11478533; expires May 13, 2040; assignee Novo Nordisk A S
    • US 11833248; expires February 1, 2039; assignee Novo Nordisk A S
    • US 12396953; expires February 1, 2039; assignee Novo Nordisk A S
    • US 12029779; expires October 10, 2038; assignee Novo Nordisk A S
    • +36 more patents

Lead sponsor's other trials

Novo Nordisk A/S, most recent start first.

Similar trials

Same condition (Renal Insufficiency, Chronic) and phase, most recent start first.